Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: A cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 11, 2017, Pages 1949-1952

  Robertson, Jamie ^a   Porter, Duncan ^b   Sattar, Naveed ^c   Packard, Chris J ^c   Caslake, Muriel ^c   McInnes, Iain ^a   McCarey, David ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

cardiovascular disease; cytokines; lipids; rheumatoid arthritis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOCILIZUMAB; ANTIRHEUMATIC AGENT; CHOLESTEROL; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; KINETICS; MALE; PARONYCHIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN ABSCESS; SYNTHESIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; EVALUATION STUDY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; INTERLEUKIN-6; KINETICS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85030995732     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211708     Document Type: Article

References (14)

1. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746-53.
2. Chung CP, Oeser A, Raggi P, et al. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 2010;37:1633-8.
3. P eters MJ, Voskuyl AE, Sattar N, et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract 2010;64:1440-3.
4. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-Analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
5. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-Analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
6. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebocontrolled study. Ann Rheum Dis 2015;74:694-702.
7. S molen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
8. Gabay C, McInnes IB, Kavanaugh A, et al. Comparison of lipid and lipid-Associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1806-12.
9. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
10. R obertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: A maturing paradigm. Nat Rev Rheumatol 2013;9:513-23.
11. S later HR, Packard CJ, Shepherd J. Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system. J Biol Chem 1982;257:307-10.
12. P ackard CJ, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000;41:305-18.
13. Gaw A, Packard CJ, Caslake MJ, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994;108:137-48.
14. Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67:616-25.